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Unnatural amino acid (UAA) incorporation by amber codon suppression offers scientists
a powerful tool to modify the properties of proteins at will. UAA incorporation has
been used for a plethora of fundamental research applications and, more recently,
also for the selective modification of therapeutic proteins. In this review most recent
developments in Escherichia coli codon expansion and, unnatural amino acid incorporation
are discussed together with some remarkable recent developments in improved efficient
UAA incorporation. We focus on the generation of proteins that hold promise for future
therapeutic applications that would be impossible to obtain without unnatural amino
acid incorporation, including the generation of bi-specific antibodies and antibody drug
conjugates.
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INTRODUCING MODIFICATIONS IN Escherichia. coli
PRODUCED PROTEINS
E. coli is the protein production workhorse of many scientists as E.
coli is suitable for large scale (industrial) production of many pro-
teins. This prokaryotic workhorse however is not able to incor-
porate most eukaryotic post-translational modifications (PTMs),
such as ubiquitination, glycosylation and phosphorylation, nor is
it capable of other eukaryotic maturation processes, and prote-
olytic protein maturation. In addition, correct disulfide bond for-
mation can be cumbersome. Lipopolysaccharide contaminations
can also be troublesome for E. coli-produced therapeutic pro-
teins, although sensitive methods for their detection and removal
exist (Lopes et al., 2010). Proteins of therapeutic significance, such
as antibodies, enzymes and cytokines, commonly carry PTMs
and disulfide bonds and often require proteolytic maturation to
attain their correctly folded active conformations. Although the
majority of therapeutic proteins are produced in eukaryotic and
mammalian cell systems, E. coli protein expression is in general
cheaper, more susceptible to genetic modifications, and versatile
with regard to mutant library development. In addition, E. coli is
fast growing and suitable for industrial scale fermentation (Huang
et al., 2012). Moreover, eukaryotic and mammalian cell systems
are prone to contamination, often require special growth media
and glycosylation systems must be frequently bypassed or dis-
abled in order to produce humanized therapeutic proteins with-
out introducing extra factors that could induce immunogenicity
(Hermeling et al., 2004; Kruszewska et al., 2008).
To take the advantages that E. coli-mediated expression offers,
several strategies have been developed to introduce mammalian
Abbreviations: UAA, Unnatural Amino Acid; PTM, Post-Translational
Modification; DsbA, Disulfide Oxidoreductase; aaRS, aminoacyl-tRNA Synthetase;
tRNA, transfer RNA; mRNA, messenger RNA; RF, Release Factor; GFP, Green
Fluorescent Protein; FACS, Fluorescence Assisted Cell Sorting; UPRT, Uracil
Phosphoribosyl transferase; IPTG, Isopropyl β-D-1-thiogalactopyranoside; PEG,
polyethylene glycol; TCR, T Cell Receptor; ADC, Antibody-Drug Conjugate.
protein modifications. If, for example, glycosylation of a recom-
binant protein is required, specialized E. coli strains can be used
that are capable of glycosylating proteins. These strains have been
developed by transplanting and adapting theN-glycosylation sys-
tem found in Campylobacter jejuni, which glycosylates similarly
to the eukaryotic glycosylation machinery (Wacker et al., 2002).
The humanized glycosylation machinery adapted from C. jejuni
and other strains are currently under development and may soon
provide glycoproteins with control over the specific glycoform
that is required in E. coli that can be used as therapeutic agents
(Schwarz et al., 2010; Terra et al., 2012). Simple eukaryotic hosts,
such as Pichia pastoris, are more frequently used to generate single
glycoforms. The company GlycoFi, for example, uses a series of
modified variants of P. pastoris to produce antibodies with specific
human N-glycan structures (Li et al., 2006).
Other strategies are needed to obtain correct disulfide forma-
tion of recombinant proteins produced in E. coli. An example
of a complex therapeutic protein is proinsulin, it consists of
two polypeptides containing 3 disulfide bridges. Rudolph et al.
showed that a fusion of pro-insulin to the periplasmic E. coli
protein; disulfide oxidoreductase (DsbA) resulted in a high-yield,
correctly folded and bioactive protein produced in E. coli (Winter
et al., 2001). The periplasm of E. coli is the most favorable
compartment for disulfide formation since it provides oxidiz-
ing conditions and contains proteins like DsbA that can catalyze
disulfide bridge formation. Efforts have also beenmade to express
disulfide-rich proteins into the cytoplasm with some success by
removing several proteins that balance the redox potential in the
cytoplasm of E. coli. (Salinas et al., 2011).
These examples show that a number of PTMs can be acquired
by clever cloning strategies and by transfer of PTM machiner-
ies from other organisms. The introduction of other eukaryotic
PMTs, e.g., lysine methylation (Nguyen et al., 2009), acetylation
(Neumann et al., 2008, 2009) and ubiquitination (Virdee et al.,
2010, 2011) has been achieved by a different approach: amber
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codon suppression to incorporate unnatural amino acids (UAAs)
(Noren et al., 1989). This technique allows for the incorpora-
tion of a single UAA (i.e., not one of the common 20 amino
acids that can be encoded) at a specific site in a protein using
a tRNA that recognizes one of the natural stop codons, the so-
called “amber” codon. Not only can PTMs be introduced by this
technique, but also various chemical handles and groups allowing
the post-expression re-design of the properties of proteins. The
focus of this review will be on the application of this technique
for the design of proteins of therapeutic value. In the first section
the amber codon suppression technique including some recently
reported developments will be discussed. In the second part cur-
rent methodologies for modifying the properties of proteins will
be discussed as well as the design of specific conjugates.
AMBER CODON SUPPRESSION
The ribosome translates mRNA into a polypeptide by com-
plementing triplet-codons with matching aminoacylated tRNAs.
Three of the 64 different triplet codons do not code for an amino
acid, but cause recruitment of a release factor resulting in disen-
gagement of the ribosome and termination of the synthesis of the
growing polypeptide. These codons are called; ochre (TAA), opal
(TGA), and amber (TAG). Of the three stop codons, the amber
codon is the least used in E. coli (∼7%) and rarely terminates
essential genes (Nakamura et al., 2000; Xie and Schultz, 2005b).
The amber codon triplet in DNA is (TAG), in mRNA (UAG),
and the corresponding tRNA anticodon is (CUA). The mRNA
triplet UAG of the amber codon, or any other stop codon nor-
mally causes the termination of translation by recruitment of one
of two release factors, RF1, and RF 2 (see Figure 1A).
Certain species do not use the amber codon as a stop codon,
but instead use it to introduce an amino acid at a stop codon. For
exampleMethanococcus jannaschii introduces a tyrosine at a UAG
codon (Wang et al., 2001). These UAG-tRNAs have been used
with great success to introduce unnatural amino acids (UAAs)
into proteins in E. coli expression systems. In order to achieve
this, a series of essential steps had to be taken (Figure 1). The
first of these is the evolution of such an orthogonal tRNA and
its related aminoacyl-tRNA synthetase (aaRS) so it no longer
recognizes a natural amino acid, but instead recognizes a UAA
of choice (Normanly et al., 1990). The evolved aaRS needs to
be orthogonal to the tRNA loading machinery of the expres-
sion host, as otherwise cross-loading of natural amino acids onto
the tRNACUA can occur (see Figure 1B). The first reported aaRS
and iso-tRNA pair that was orthogonal to the E. coli expres-
sion machinery was derived from the aforementioned archaea
Methanococcus jannaschii, where it normally encodes for a tyro-
sine residue (Wang et al., 2001). The tRNACUA pair could be
readily mutated to accept an unnatural amino acid, because the
aaRS has minimal interaction with the anticodon of its tRNACUA.
The minimalist anticodon recognition of the aaRS to its tRNA
makes it possible to mutate the aaRS amino acid binding pocket
from tyrosine to an UAA with little loss of affinity and aminoacy-
lation efficiency of the aaRS for the tRNA (Steer and Schimmel,
1999). Furthermore, the lack of an editing mechanism capable
of deacylating the UAA and high expression levels are the fea-
tures that have made this pair so successful for E. coli (Xie and
Schultz, 2005a). This success has been further compounded when
the crystal structure of an evolved M. jannaschii tyrosyl-RS, the
p-cyanophenylalanine-specific aaRS, was solved revealing the rea-
son for its atypical polysubstrate (more than 18 UAAs) specificity
of this evolved aaRS (Young et al., 2011). This structure has been
used for a study that uses molecular modeling and docking to
design optimal mutations for a given UAA (Armen et al., 2010).
Takimoto et al. in 2011 published a structure of aaRS
for pyrrolysine (Takimoto et al., 2011), which is a second
aaRS/tRNACUA that is often used to incorporate UAAs. This
exotic aaRS was found in the archaea Methanosarcina mazei and
aminoacylates the 22nd genetically encoded natural amino acid
pyrrolysine onto a rare tRNACUA with an amber codon [the 21st
genetically encoded amino acid is selenocysteine with a tRNAUCA
opal codon (Stadtman, 1996)]. The authors showed that they
could evolve the pyrrolysyl-RS on the basis of the crystal structure
to accept and aminoacylate the tRNACUA with UAAs with short
FIGURE 1 | Incorporation of UAAs into proteins allows selective
modifications. (A) Normal translation is terminated by the recruitment of
release factors. In the case of an amber codon, release factor 1 (RF1) is
recruited and terminates the translation of the polypeptide rereleasing the
newly synthesized protein. (B) Amber codon suppression to incorporate
unnatural amino acids (UAA) makes use of the amber codon as a coding
codon in translation. The complementary amber tRNACUA is aminoacylated
by an orthogonal aminoacyl-tRNA synthetase (aaRS) that is specifically
designed to accept only unnatural amino acids. This results in a protein with
an UAA incorporated. (C) Subsequently, this protein can be selectively
modified via chemoselective chemical modification, only reacting with the
UAA incorporated in the protein, leaving all other groups in the protein
unaffected. In this manner, defined proteins of therapeutic interest can be
generated.
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aromatic side chains, in contrast to the long aliphatic side chain
of the native substrate pyrrolysine.
MUTANT SELECTIONWITH SINGLE GENETIC CONSTRUCTS
The classical method to generate UAA-accepting mutants
(explained in Figure 2) of orthogonal aaRS and iso-tRNA pairs
for E. coli (Xie and Schultz, 2005b), as described by P.G. Schultz, is
cumbersome as it requires multiple steps of plasmid purification
and transformation. (Wang and Schultz, 2001). Extensive efforts
have been made to optimize mutant selections that require fewer
steps compared to the classic method described in Figure 2 and
enable researchers to perform faster selections of desired mutants.
One of these methods was described by Santoro et al. in 2002,
where a single genetic construct carrying both the genes for the
orthogonal aaRS and iso-tRNA pair from M. jannaschii with
a chloramphenicol-resistance reporter was used to select highly
active aaRS variants in one step (Santoro et al., 2002). In addi-
tion, this system contained a T7 RNA polymerase with an amber
codon and a green fluorescent protein (GFP) reporter protein
construct under the T7 promoter. So only mutants with effective
orthogonal aaRS and iso-tRNA pairs could express GFP through
T7 promoter induced expression by the amber-encoded T7 RNA
polymerase. By making mutations in the amino acid binding site
of the aaRS in this genetic construct, libraries of mutants were
obtained that efficiently suppressed the amber codon. By FACS-
sorting of GFP positive E. coli cells from the non-fluorescent cells,
multiple rounds of optimizations were easily performed.
A new series of selection vectors was developed by Melancon
3rd et al. They reported a dual positive/negative selection sys-
tem for the evolution of aaRS with altered specificities in E.
coli (Melancon and Schultz, 2009). This specific plasmid utilized
a chloramphenicol acetyltransferase-uracil phosphoribosyltrans-
ferase (UPRT) fusion gene which was used as a dual positive/
negative selection marker. UPRT is an enzyme that can con-
vert 5-fluorouracil to 5-fluorouracil mono phosphate (Rackham
and Chin, 2005). The converted 5-fluorouracil monophosphate
is an inhibitor for the essential thymidylate synthase. This essen-
tial enzyme generates thymidine monophosphate, which is sub-
sequently phosphorylated to thymidine triphosphate for DNA
synthesis. In the chloramphenicol transferase part of the fusion
protein with UPRT, an amber codon was inserted at a tolerated
position. The activity of the amber suppression was selected for
in the positive selection step by growing the E. coli in the presence
of both chloramphenicol and an UAA. Next the negative selection
was performed in the presence of 5-fluorouracil.
The most recent improvement to the method for generat-
ing amber codon mutants was the development of the plasmid
pEVOL (Young et al., 2010). Young et al. developed a system
through the use of both constitutive and inducible promoters,
based on a plasmid described by Celliti et al. (Cellitti et al., 2008).
The constitutive promoter glnS’ (Plumbridge and Soll, 1987) and
the inducible arabinose promoter araBAD (Guzman et al., 1995)
drove the transcription of two copies of the p-cyanophenylalanine
specific aaRS from M. jannaschii. (Wang et al., 2001). The advan-
tage of having both a constitutive and an inducible promoter for
the aaRS is that there is a basal level present of the aaRS by the
constitutive promoter and when protein expression is induced
increased levels of the aaRS are obtained by the addition of arabi-
nose. The tRNACAU was optimized by mutating several positions
in the tRNA called the T-stem, and was put under the proK
promoter of which it is reported to be highly efficient in the tran-
scription of single or multiple copies of the tRNACAU (Ryu and
Schultz, 2006). With the pEVOL vector they efficiently incorpo-
rated an UAA in the model protein GroEL which they expressed
in approximately 100mg per liter culture medium.
However, this pEVOL is still a widespread used method to
obtain amber codon mutants, this system has now been extended
with the addition of a new plasmid-system: pUltra (Chatterjee
et al., 2013). This novel dual system allows single- and multiple-
UAA mutagenesis in E. coli in combination with the previously
reported pEVOL amber-suppressor plasmid. The pUltra sys-
tem encodes both an amber (M. jannaschii tyrosyl tRNA/aaRS
pairs) and an ochre (M. barkeri pyrrolysyl) suppression system.
Furthermore, a novel replication origin and antibiotic resistance
marker (spectinomycin) allowed an orthogonal use in combina-
tion with pEVOL. The described suppression efficiency and the
versatility to usemultiple UAA orthogonal tRNA-aaRS pairs using
this pEVOLV/pUltra system show that the UAA-field is constantly
improving and revolutionizing.
RELEASE FACTOR 1 KNOCKOUT AND AMBER CODON
REPLACEMENT FOR INCREASED AMBER CODON
SUPPRESSION
A major drawback of amber codon suppression in eukaryotic
and prokaryotic cell expression systems is the presence of the
amber-recognizing release factor protein 1 (RF1). Prokaryotes
terminate translation by RF1 and RF2, where RF1 recognizes the
mRNA stop codons UAA (ochre) and UAG (amber), RF2 rec-
ognizes UAA (ochre) and UGA (opal) (Scolnick et al., 1968).
When the amber codon is reassigned to incorporate an UAA, the
tRNACUA is always in competition with RF1, resulting in trun-
cations of the desired protein at the amber position. It has been
commonly accepted that both RF1 and RF2 are essential for E.
coli, and knock-out of one of the RFs is lethal (Gerdes et al., 2003).
This lethality is due to a few essential genes with amber codons.
However, recent reports describe strains in which the RF1 gene is
disabled increasing the amber codon suppression efficiency.
An RF1 knockout was first generated in E. coli by Mukai
et al., This strain was viable as long as seven essential genes
along with the suppressor tRNA were complemented on a plas-
mid (Mukai et al., 2010). The result was an increasing yield of
full-length proteins containing UAAs, because of the lack of trans-
lation termination by RF1. D. B. F. Johnson et al. reported the
knockout of RF1 by a different approach requiring no addition
of any other genes or a suppressor tRNACAU. They created an
E. coli strain termed JX33 which is RF1 independent, suggest-
ing that RF1 is non-essential in this strain. They complemented
these results by expressing GFP in this strain containing up to
10-p-acetylphenylalanine (pActF) moieties into designed GFP
reporters. (Johnson et al., 2011). Shortly after these findings
D. B. F. Johnson et al. reported that a mutation in RF2 (thre-
onine 246 to alanine) allowed to knockout RF1 in certain E.
coli strains. RF2 recognizes the stopcodons UAA and UGA. The
shared stopcodon UAA between RF1 and RF2 in the E. coli
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FIGURE 2 | Classic method for evolving orthogonal aminoacyl-tRNA-
synthetases and iso-tRNA pairs for E. coli. To incorporate UAAs in
proteins expressed in E. coli, an orthogonal aaRS and iso-tRNA pair need to
be evolved such that they do not cross-react with the endogenous E. coli
expression machinery. The orthogonal pair uses an amber stop codon as a
coding codon to incorporate an UAA into the protein of interest. Multiple
rounds of positive and negative selections are usually carried out to obtain
the orthogonality toward the E. coli expression machinery. (A) First, a
tRNACUA mutant library with an amber codon anticodon is transformed into
E. coli. To ensure that the endogenous E. coli aaRS does not aminoacylates
the tRNACUA, an amber-encoded toxic barnase protein is co-expressed. If an
endogenous E. coli aaRS aminoacylates the tRNACUA, the cell dies because
the toxic barnase protein is expressed. (B) Next, the tRNAs that are not
aminoacylated by the endogenous E. coli aaRS survive and are co-expressed
with a heterologous aaRS mutant library. In this positive round the cells
grow in the presence of the antibiotic ampicillin. If a heterologous aaRS
aminoacylate the tRNACUA, the cells survive, because they express the
amber-encoded β-lactamase protein, allowing the cells with an aaRS that can
aminoacylate the tRNACUA to survive in the presence of the antibiotic
ampicillin. (C) To select for mutant aaRS that can aminoacylate the tRNACUA
with an UAA, the UAA is added to the growth medium of E. coli and the
cells grow in the presence of the antibiotic chloramphenicol. The aaRS that
aminoacylate with either the UAA or a natural amino acid survive because
an amber-encoded chloramphenicol acetyltransferase is expressed. To select
for mutant aaRS that can only aminoacylate with the UAA the mutant library
with the aaRS and the tRNACAU are transferred. (D) The cells are now
grown in the absence of the UAA. Cells containing mutant aaRS that
aminoacylate the tRNACUA with a natural amino acid die, because they
express the amber-encoded toxic barnase protein. Only the UAA specific
aaRS and tRNACAU pairs survive, because they are orthogonal to the E. coli
expression machinery (Wang and Schultz, 2001; Wang et al., 2001; Xie and
Schultz, 2005b).
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genome terminates ∼64% of the genes (Nakamura et al., 2000).
Johnson et al. hypothesize that the alanine 246 to threoninemuta-
tion in RF2 decreases the affinity for UAA. The E. coli strains they
used to create the RF1 knockout all have an alanine at position
246, suggesting that the A246 in required for efficient termination
of the abundant UAA and UGA stop codons in E. coli.
The authors also showed that for their E. coli strains used, only
7 of the 302 essential genes end with UAG. Additionally, these 7
essential UAG amber-stop codon genes all have an UGA or UAA
second stop codon downstream in short distance of their amber-
stop codon. If the amber codon is suppressed, the essential genes
are “saved” by the second stop codon termination of these pro-
teins by RF2, with only a small number of amino acids added to
the essential genes (Johnson et al., 2012).
Next to RF1 knockout, enhanced amber codon suppression
could be even further exploited by genomic manipulations of
the E. coli endogenous genome. As mentioned before the amber
codon is the least used in E. coli (∼7%) and rarely terminates
essential genes (Nakamura et al., 2000). Isaacs et al. re-engineered
the E. coli genome to remove all 314 amber codons and replaced
them with ochre codons abolishing the genetic dependence on
RF1 (Isaacs et al., 2011).
FOUR-BASE BLANK CODONS AND EVOLVED RIBOSOMES
The one major limitation to amber codon suppression is that it
only allows the replacement with one type of amino acid. In order
to encode multiple distinct UAAs into proteins the use of new
“blank” codons has been explored. These blank codons require
aaRS and iso-tRNA pairs that can decode these blank codons.
One example of a further expansion of the genetic code made
use of orthogonal aaRS and iso-tRNA pairs that recognize four-
base codons. This would in theory provide 256 blank quadruplet
codons, and with larger codons even more blank codons are the-
oretically possible (Anderson et al., 2002; Wang et al., 2012). The
use of four-base codons is elegantly applied to Ribo-X, which
is an evolved orthogonal ribosome developed by J. Chin and
coworkers (Rackham and Chin, 2005). His team demonstrated
the synthetic evolution of an orthogonal ribosome, Ribo-X that
increased the efficiency of amber codon suppression. They com-
bined Ribo-X with an orthogonal aaRS and iso-tRNA pair from
M. jannaschii and an orthogonal mRNA. Using this method they
substantially increased the efficiency of site specific UAA incorpo-
ration in E. coli. The Ribo-X discriminates the orthogonal mRNA
by a designed sequence that allows only the synthesis of UAA
encoded proteins (Rackham and Chin, 2005). They hypothesized
that their Ribo-X has less functional interaction with RF1, allow-
ing the tRNACAU to more efficiently compete for the binding
in the presence of an UAG amber mRNA codon (Wang et al.,
2007). Although Ribo-X has allowed to incorporate an UAA at
two sites with reasonable efficiency (∼20% for 2 amber codon
sites with Ribo-X and <1% for normal ribosomes), RF1 knock-
out in the JX33 strain showed higher UAA incorporation of a
reporter protein with multiple amber codon sites (Johnson et al.,
2011). In 2010 J. Chin and coworkers used their evolved ribo-
somes (Ribo-X, evolved to Ribo-Q1) to incorporate two UAAs
into the protein Calmodulin. Calmodulin fusion protein con-
tained an AGGA codon at position 1 and an amber codon at
position 40 of calmodulin. The full length protein was produced
with yields up to 0.5mg per liter culture (Neumann et al., 2010).
SELECTIVE BIOORTHOGONAL CHEMICAL MODIFICATION
FOR UAAs
The list of UAAs incorporated into proteins is rapidly growing
and other papers review list the growing number of UAAs that
can be incorporated in this manner (Budisa, 2004; Hendrickson
et al., 2004; Liu and Schultz, 2010; Neumann, 2012). Although the
repertoire of UAAs is broad and increasing constantly, in order
to use the UAAs for chemical couplings, the reactions should
be chemo-selective, bioorthogonal and mild, preserving the fold,
and function of the proteins (see Figure 1C). For every new
UAA, chemical modifications have to be experimentally deter-
mined, fortunately an abundance of invaluable bioorthogonal
chemistries for chemoselective protein modifications is described
that can help scientists to choose the appropriate reaction for
their purpose and protein of interest, (Sharpless, 2002; Prescher
and Bertozzi, 2005; Meldal and Tornoe, 2008; Best, 2009; de
Graaf et al., 2009; Sletten and Bertozzi, 2009; Lim and Lin,
2010).
E. coli PRODUCED THERAPEUTIC PROTEINS AND AMBER
CODON SUPPRESSION
Despite the numerous technical advances, themain difficulty with
UAA incorporation using amber codon suppression is the protein
yield. Especially when producing proteins containing multiple
UAAs, expression levels are low, which, for now prevents their use
in the production of therapeutic proteins. There have been recent
advances, however, in the production and use of therapeutic
proteins carrying single UAAs, which will be discussed
below.
There are numerous examples of therapeutic proteins; insulin
for diabetes, human growth hormones for growth deficiencies,
antibodies, cytokines and interferons for cancer immunother-
apy and several enzymes and blood factors for heart attacks and
strokes. Recombinant E. coli produced human insulin (Humulin)
was the first recombinant human therapeutic protein (Strohl and
Knight, 2009). Humulin was developed together by Genentech
and Eli Lilly, and first approved for use in 1982 (Strohl and
Knight, 2009). Nearly 30% of currently approved recombinant
proteins are produced in E. coli and the recent advancements are
reviewed (Huang et al., 2012) and clinically relevant therapeutic
proteins have been reviewed thoroughly elsewhere (Leader et al.,
2008).
PEGylation AND UAAMODIFICATIONS OF SERUM PROTEINS
Common features of (recombinant) therapeutic proteins are: a
high molecular weight, short half-life and a tendency to become
immunogenic to the patient after prolonged use (Hermeling
et al., 2004). Another disadvantage can be found in the deliv-
ery of these proteins: daily administrations via injections are
often necessary to maintain sufficient levels of the protein in
the body. In order to overcome these problems therapeutic
proteins are frequently modified to enhance their pharmaco-
logical properties. The covalent attachment polyethylene glycol
chains (PEG) can improve stability of proteins in vivo (Pisal
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et al., 2010; Payne et al., 2011). Chemical strategies to mod-
ify these proteins are usually limited to the N-terminal amino
group, the C-terminal carboxylic acid, the ε-amino group of
lysine or thiol-groups like cysteine. Modifications at the ter-
mini can alter the function of proteins and lysine and cysteine
side chain modifications can occur at multiple positions within
a protein, making selective modification challenging and fre-
quently yielding heterogeneous products. In addition, the lack
of selectivity modifying a protein can lead to loss of biological
activity and possibly an increase in immunogenicity (Hermeling
et al., 2004). Coupling conditions to connect molecules such
as PEG to a protein should be sufficiently mild, to leave the
integrity of the protein intact. Whereas exploiting the ε-amino
group of lysine to covalently modify it with PEG generally yields
heterogeneous products, for homogenous proteins site-specific
reactive groups can be inserted into proteins by amber codon
suppression. Not only PEG can be introduced in this manner,
PTMs from higher eukaryotes, for example sulfonated tyrosine
can be introduced by UAA incorporation as well (Liu et al.,
2007).
An excellent example of introducing PEG in a site-specific
manner is the paper of Deiters et al., where they report a
PEGylation methodology based on the site-specific incorporation
of p-azidophenylalanine in the enzyme superoxide dismutase
(Deiters et al., 2004). Using a mild [3 + 2] cycloaddition between
the incorporated azido group on the phenylalanine and an alkyne
derivative of PEG with copper Cu(I) catalysis they obtained a
superoxide dismutase modified with a stable triazole linked PEG
chain (Wang et al., 2003) without a significant loss of superoxide
dismutase activity (Veronese et al., 2002).
In 2011 Cho et al. further developed PEGylation methodology
by site-specific incorporation of PEG in human growth hormone.
They incorporated p-acetylphenylalanine at distinct locations in
human growth hormone and by the orthogonal chemical reac-
tivity of the p-acetyl group of the UAA they formed a covalent
oxime bond with an amino-oxy terminated PEG. With this strat-
egy they made 20 different homogeneous forms of PEGylated
human growth hormone on a large scale by high density fer-
mentations that have been carried out a 1000 liter scale, yielding
500–800mg per liter of UAA incorporated human growth hor-
mone. They tested the activity, stability, half-life, and safety of the
UAA PEGylated human growth hormone in preclinical rodent
studies. The Tyr35 to p-acetylphenylalanine mutant form of
human growth hormone was tested in growth hormone-deficient
adult patients for the tolerability, safety, half-life, and IGF-1
response and showed efficacy and safety that complemented or
exceeded daily therapy with human growth hormone produced
in mammalian cells (Cho et al., 2011).
Another example of a therapeutic protein modified through
amber codon suppression is Hirudin. This protein is an anti-
coagulant that inhibits thrombin. This therapeutic protein is
extracted from leeches and the natural protein contains a sul-
fonated tyrosine residue. Recombinant E. coli expressed hirudin
(thus without sulfation of this tyrosine residue) has approxi-
mately 10-fold less affinity over the sulfo-hirudin isolated from
leeches. By site-specific incorporation of sulfotyrosine, Lui et al.
generated a biosynthetic E. coli-produced sulfo-hirudin by amber
codon suppression. Although the yields were low (5mg per liter)
for the sulfo-hirudin produced by E. coli and amber codon sup-
pression they made a co-crystal of sulfo-hirudin and thrombin.
Something that was not possible before with the low amounts of
hirudin extracted from leeches (Liu et al., 2007).
These examples have shown that be either controlling the
PEGylation or by incorporating UAAs in a site-specific manner,
improved therapeutic proteins are obtained in a defined and con-
trolled manner which resulted in modified proteins with better
therapeutic value. (de Oliveira et al., 1999; Jung et al., 2011).
E. coli PRODUCED ANTIBODIES: MODIFICATIONS AND
ADVANCEMENTS
Antibodies are well recognized as proteins of therapeutic value
and are important therapeutically for a wide range of diseases,
such as autoimmunity and cancer therapy. As such there are many
efforts ongoing in order to improve the effector functions of ther-
apeutic antibodies. Several modified antibodies are used in the
clinic or evaluated in clinical trials. Although none of the reported
antibodies are capable of curing cancer as a single agent, (Chames
and Baty, 2009) specific antibodies can improve the clinical out-
come of cancer, autoimmune disease, transplant rejection or can
bind toxins (e.g., snake venom toxins). The use of therapeutic
antibodies is reviewed elsewhere (Leader et al., 2008).
Extensive research has been conducted in order to produce
humanized N297 N-glycosylated IgG antibodies. This N-linked
glycan affects the therapeutic properties of antibodies by recruit-
ing innate immunity effector cells and serum proteins, such
as complement system proteins. Recruitment of these effectors
can lead to targeted cell death, which is a desirable property in
cancer immunotherapy. Many efforts have been made and sev-
eral systems have been developed [mammalian, non-mammalian
expression systems, like the GlycoFl-engineered P. pastoris from
GlycoFi, mentioned before (Li et al., 2006)] to obtain glycosy-
lated IgG antibodies. Although N-linked glycosylated N297 is
the natural glycosylated residue found in human IgG antibodies,
unglycosylated antibodies can be produced in E. coli and some
of these recombinant antibodies are in clinical trials. So far, all
clinically approved therapeutic antibodies have been produced in
fused mouse myeloma cells or Chinese hamster ovarian (CHO)
cells (Jung et al., 2011). Despite the fact that no approved ther-
apeutic antibodies are from E. coli origin, E. coli still remains
an attractive system to produce non-glycosylated antibodies and
continuing efforts are made to scale up the production including
methods that use heat-inducible expression (Bayly et al., 2002)
and metabolic engineering (Makino et al., 2011).
Another example of ongoing developments includes the pro-
duction of Iclonals. These E. coli produced and refolded IgG
antibodies and antibody-toxin fusion proteins show similar bind-
ing affinities compared to mammalian cell culture antibodies.
Using the Iclonal technique, 50mg of pure, refolded antibody
was obtained from 1 liter shake flask cultures by Hakim et al.
(Hakim and Benhar, 2009). The benefit of this system is the speed;
antibodies were obtained in these amounts within in 8–9 days,
compared to the multi-week process for a mammalian expression
system. In the next example we discuss how UAA incorpora-
tion can provide more flexibility and versatility and can be used
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to create therapeutic bispecific antibodies and antibody-drug
conjugates.
BISPECIFIC ANTIBODIES
One of the most recent examples of using amber codon sup-
pression to incorporate UAAs in an E. coli produced antibody
is the synthesis of a bispecific antibody as recently described
by Schultz and coworkers. An anti-HER2 /anti-CD3 bispecific
antibody was constructed, using the fragment antigen binding
domains of both antibodies (see Figure 3A) (Kim et al., 2012).
The CD3 protein is associated with the T cell receptor (TCR)
of mature CD8+ T cells. These cytotoxic CD8+ T cells can
kill both virus-infected cells and tumor cells. Their TCR and
CD8+ receptors have evolved to detect intracellular pathogens
and tumor cells by recognition of peptides, derived from viruses
and tumor proteins, displayed on the cell surface by MHC class I
molecules. Once presented on the cell surface inMHC complexes,
T-cells can recognize them and kill the target-cell by releasing
FIGURE 3 | Examples of reported antibodies and screening methods
with pharmacological relevance. (A) Bispecific antibody against HER2 and
CD3 linked together through an UAA. The basic principle of a bispecific
antibody is that it can bring two targets together. Our immune system can
eradicate cancer cells, through recognition by killer immune cells that destroy
them (Chames and Baty, 2009). As depicted, a bispecific antibody can bring
cytotoxic T cells in contact with the cell surface receptor HER2, frequently
found over-expressed in breast cancer cells (Kim et al., 2012). (B) Structural
overview of an antibody drug conjugate (ADC). Through specific targeting of a
plasma membrane marker (example: fibronectin, a marker of tumor
angiogenesis) a bound drug (example: cytotoxic drug) can be released to the
targeted marker (Bernardes et al., 2012). Until now, only natural amino acids,
like cysteine, are used to conjugate cytotoxic drugs to the antibodies through
thiol-bonds. (C) Antibody library formats in E. coli are used to screen for
antibodies with improved affinity for their antigen. The antibodies are
expressed in E. coli and displayed on the inner-membrane. By
outer-membrane permeabilization the antibodies are exposed and suitable for
FACS-mediated sorting with fluorescently labeled antigens (Mazor et al., 2010).
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cytotoxins to kill the infected or tumor target-cell. As a result
of the efforts of Schultz and coworkers a remarkable molecule
was constructed that brings T cells to HER2-expressing (breast
cancer) cells with in vitro effector-cell mediated cytotoxicity at
picomolar concentrations. Thus, this approach brings a T cell in
close proximity to a HER2-expressing breast cancer cells to form a
cytotoxic synapse. Tumors frequently escape immune surveillance
by down-regulatingMHC class I antigen presentation, preventing
cytotoxic CD8+ T cells from recognition and clearance (Seliger,
2008).
For the construction of the bispecific HER2-CD3 bispecific
antibody, a similar approach as described in the paper from
Schultz was used where p-acetylphenylalanine was incorporated
at distinct locations in human growth hormone to couple a PEG
moeity (Cho et al., 2011). In this study p-acetylphenylalanine was
incorporated in mutant Fab fragments of an antibody that rec-
ognizes HER2 (Herceptin, Cho et al., 2003) and (CD3 UCHT1,
Zhu and Carter, 1995) by amber codon suppression. Then the
two antibody fragments were selectively coupled by a stable oxime
bond to bifunctional linkers with an alkoxy-amine on one termi-
nus and an azide or cyclooctyne group at the other. Next they
coupled the two bifunctional linkers to obtain the bispecific anti-
body by a copper-free [3 + 2] Huisgen cycloaddition (Jewett and
Bertozzi, 2010).
The use of an UAA provided in the given example can cer-
tainly be applied to other antibody fragments. Linker fragments
can be modified and optimized in order to obtain the right flexi-
bility and affinity needed for the bispecific antibody. In addition,
UAA incorporation can provide more specificity and flexibility,
with regard to standard bispecific antibody generation. In the
review from Chames and Baty most recent clinical trials involv-
ing the use of bispecific antibodies (and other antibody-formats)
are listed and the authors describe the success of these thera-
peutic antibodies in great detail (Chames and Baty, 2009). The
previous example of the HER2-CD3 bispecific antibody is one of
many combinations that are possible. Most bispecific antibodies
use the reactivity of lysine and cysteine leading to heterogeneous
products. The advantage of site-specific incorporation of UAAs
compatible with crosslinking is that they are bioorthogonal and
yield a single defined product, which is difficult to obtain through
standard amino acid coupling chemistries.
ANTIBODY DRUG CONJUGATES
A different use of modified antibodies comes in the form of
antibody-drug conjugates (ADCs). Here a drug can be targeted
to a receptor that is up-regulated in various malignant cells. For
example, the human epidermal growth factor receptor 2 (HER2)
is frequently found over-expressed in breast cancer cells and
provides a target that can be used for ADCs. In addition, the
transferring receptor and the epidermal growth factor receptor
are often used targets to combat cancer (Daniels et al., 2006;
Dhomen et al., 2012). We point the reader to two reviews (Chari,
2008; Senter, 2009) that list the majority of ADCs, used link-
ers and their bound drug targets. The ADC approach of delivery
makes it possible to use potent, but highly toxic drugs that can-
not be applied systemically because they cause side effects due to
off-targeted effects (i.e., side-effects of the drug affecting healthy
cells). By using ADCs potent drugs can accumulate at the tumor
site, avoiding the systemic toxicity and side effects. There are sev-
eral mechanisms in how an ADC can release the drug to the target
and the mode of action depends on the specificity of the anti-
body. The first mechanism is continuous internalization. Once
the ADC is bound to its target it will get internalized eventually
and the drug bound to the antibody can be released in various
ways, including proteolysis and pH-mediated drug release. Other
mechanisms include ADC accumulation, before internalization
and in other cases the drug can be released at the site of inter-
est through a different environment (Chari, 2008). For example,
as a tumor grows, tumor cell lysis mediated glutathione and cys-
teine release to the tumor microenvironment allows the drug to
be released from the ADC in a target-specific manner (Bernardes
et al., 2012).
Most ADCs are based on the reactivity of thiol groups present
as cysteine (see Figure 3B). A recent publication from Axup
et al. has applied unnatural amino acid incorporation to site-
specifically make an ADC (Axup et al., 2012). Here they have
designed an HER-2 Fab fragment in E. coli and a full length
IgG in mammalian CHO cells with high yields of 400mg/ml and
300mg/mL, respectively using high-density fermenters. Via the
site-specifically incorporated p-acetylphenylalanine they coupled
the microtubule toxin auritstatin through a stable oxime-ligation.
Both the ADC Fab and ADC IgG full length were converted with a
yield of >95%, making this approach very suitable for preparing
homogeneous, well-defined ADC’s.
This example demonstrates that the use of UAA incorporation
can benefit the preparation of a site-specific ADC. There have
been reports of near-homogeneous ADC preparations and site-
specific coupling a cysteine in ADCs with great efficacy and potent
activities in vivo (Junutula et al., 2008; Bernardes et al., 2012). This
near-homogeneous approached used the reactive thiol in cysteine
for coupling maleimide-drugs. These thiol-based reactions can
influence the ADC stability and therapeutic activity (Shen et al.,
2012). Difficulties formaleimide chemistry involve disulfide bond
reduction reoxidation procedures. Here, UAA incorporation pro-
vides more gentle coupling chemistries and offers a more versatile
tool to define the position of the drug and the use of cleavable and
non-cleavable linkers.
ANTIBODY LIBRARIES PRODUCED IN E. coli
In general E. coli–based antibody libraries are not as success-
ful as other formats reported, like yeast- or phage-antibody
display libraries (Boder et al., 2000). E. coli is limited by its
antibody expression, secretion and folding. An important factor
for an antibody screening-library is the accessibility and cellular
localization of the antibody (Hoogenboom, 2005). Nevertheless,
to identify antibodies with improved affinity for their antigen,
mutant-based libraries in E. coli can be used. In the review by
Hoogenboom the most important library formats are discussed
and the various antibody and antibody-like proteins that can
be obtained from these libraries is demonstrated (Hoogenboom,
2005).
To overcome this major drawback of E. coli based antibody-
libraries, Mazor et al. developed an elegant technique to obtain
full length antibodies from E. coli. They selected for full-length
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IgG antibodies displayed on E. coli by assembling these anti-
bodies in the periplasm of E. coli. The authors expressed an
antibody binding protein in the inner-membrane of E. coli to
bind the antibody produced and by subsequent outer-membrane
permeabilization the antibodies were assessable to fluorescently
labeled antigens. By binding these fluorescently labeled antigens
to the outer-membrane permeabilized E. coli cells, they could
select for strong-binding IgGs in multiple rounds of FACS (see
Figure 3C). The obtained antibodies were reported to be well
expressed in E. coli and had nanomolar affinity (Mazor et al.,
2007, 2008).
Two papers that use UAA incorporation in combination
with library display in E. coli come from the Schultz lab and
these efforts resulted in significantly improved antibody affini-
ties upon UAA incorporation. In the first examples the authors
genetically incorporated sulfotyrosine into gp120 antibodies by
amber codon suppression. It is of note that a specific anti-
body found in human HIV patients contains two sulfotyro-
sine residues and participate in the strong interaction for the
gp120 envelope glycoprotein of HIV (Choe et al., 2003). Based
on this PTM from this antibody, the authors made a phage-
display library of amber codon mutant antibodies and showed
that it is feasible to combine a library screening approach
with UAA incorporation (Liu et al., 2008, 2009a). In a more
recent example from the Schultz lab a genetically encoded p-
boronophenylalanine, was incorporated in order to trap diols
that are present in carbohydrates through the selective for-
mation of boronic acid esters. The single-chain variable-chain
antibody phage library was then used to select for antibod-
ies that can trap glucamine. By performing multiple enrich-
ment rounds they could obtain about 80% of clones con-
taining the UAA after three rounds of selection (Liu et al.,
2009b).
Besides altering UAA incorporated antibodies, there have been
widespread efforts in the protein engineering field to manipulate
antibody fragments, design protein scaffolds and create non-Ig-
binding proteins like affibodies. These non-Ig-binding proteins
are designed to bind protein targets and are greatly suitable for
randomized libraries of mutants. Some of these novel engineered
therapeutic proteins have progressed into the clinic for targeted
cancer therapy, regulated drug delivery, and in vivo imaging.
Affibodies and other new alternate antibody scaffolds which could
benefit from UAA incorporation have been reviewed in detail
(Banta et al., 2013).
FUTURE APPLICATIONS OF UAA INCORPORATION
Numerous future applications can be thought of by comb-
ing existing techniques and UAA incorporation for protein
FIGURE 4 | Future applications of unnatural amino acid incorporation for
the development of proteins with therapeutic value. In this example the
antibody format described by Mazor et al. is used to combine UAA
incorporation with E. coli-based screening formats (Mazor et al., 2010). An
aaRS mutant and tRNA mutant library can be cross-combined with an
antibody mutant library. Together with unnatural amino acid libraries, screens
can be performed on viable mutants expressing antibodies with improved
affinities toward a fluorescent antigen. To make this screening process more
efficient, an E. coli strain with an RF1 knock-out (Johnson et al., 2012) and
evolved ribosomes (Wang et al., 2012) can be used. By combining this, amber
codon suppression and four-base codon suppression could yield promising
and undiscovered therapeutic proteins.
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modification. Next, we will briefly discuss these applications of
the future that may hold promise for the development of novel
therapeutic modalities.
Since it is possible to combine UAA incorporation with library
based selection procedures, a next generation of antibodies, pro-
tein scaffolds, and non-Ig-binding proteins could be obtained by
making use of the techniques described here and by combining
them. This is not limited to the creation of bispecific antibod-
ies as described earlier, or the use of a single defined UAA to
screen for improved antibodies. Multiple UAA incorporation can
be used to incorporate different UAAs to improve the affinity of
antibodies toward their antigen. In a similar fashion orthogonal
aaRS and iso-tRNA libraries can be co-transformed into E. coli to
obtain mutant antibodies with incorporated UAAs, provided that
appropriate selection procedures are in place (see Figure 4).
By combining E. coli mutant libraries with a library of UAAs
new and possibly highly potent antibodies or other proteins could
be engineered. Since all the techniques are currently available,
next-generation therapeutic proteins can be identified exploit-
ing the advances of UAA incorporation in more straightforward
manners. Not only increased target affinities of proteins with ther-
apeutic value through the incorporation of UAAs can be expected,
also metabolic stabilities can be altered in this manner as proteins
can now be designed to become resistant to proteolysis or early
secretion.
Although UAA incorporation has enormous promise, it is
also in its infancy and significant hurdles are currently being
addressed. The technique is currently far from routine, how-
ever in the near future it may be part of the toolbox available
for drug design. Engineering the E. coli to increase the effi-
ciency of amber codon suppression and UAA incorporation are
in currently being intensely investigated as evidenced by the
recent publication of the RF1 knockout E. coli strain JX33,
that allows the incorporation of multiple UAAs in one pro-
tein and genome wide amber codon replacement (Isaacs et al.,
2011; Johnson et al., 2011). In addition the generation of sin-
gle genetic constructs for orthogonal aaRS and iso-tRNA pairs
has made it easier to mutate and screen for efficient amber
codon suppression. The introduction of evolved ribosomes and
four-base codons, UAA incorporation has enabled the incorpo-
ration of more than one defined UAA per protein, although
increasing the efficiency of incorporation of multiple UAAs
is still problematic and more technological developments are
needed in order to make it applicable for future therapeutic
applications.
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